[go: up one dir, main page]

JP2000297044A - Transdermal patch for external use for skin - Google Patents

Transdermal patch for external use for skin

Info

Publication number
JP2000297044A
JP2000297044A JP11105073A JP10507399A JP2000297044A JP 2000297044 A JP2000297044 A JP 2000297044A JP 11105073 A JP11105073 A JP 11105073A JP 10507399 A JP10507399 A JP 10507399A JP 2000297044 A JP2000297044 A JP 2000297044A
Authority
JP
Japan
Prior art keywords
extract
skin
antipruritic
agent
patch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP11105073A
Other languages
Japanese (ja)
Inventor
Tamotsu Nagao
保 長尾
Naoki Morita
直毅 盛田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunstar Inc
Original Assignee
Sunstar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunstar Inc filed Critical Sunstar Inc
Priority to JP11105073A priority Critical patent/JP2000297044A/en
Publication of JP2000297044A publication Critical patent/JP2000297044A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PROBLEM TO BE SOLVED: To obtain the subject transdermal patch for external use that has excellent sustainability and antipruritic effect by using at least one selected from an extract of a plant, Artemisia princeps, an antihistaminic agent and antipruritic agent. SOLUTION: This transdermal patch agent includes (A) an Artemisia princeps extract, (B) antihistamine agent and antipruritic agent. In a preferred embodiment, additionally, (C) at least one kind of plant extract selected from root of Sanguisorba officinalis, leaves of Juniperus communis, leaves of Japan cedar, Lotus root, root of Panax notoginseng, Lycium barbarum, madder and Sophora angustifolia and (D) a microbicide. The Artemisia princeps extract is prepared from leaves, stems and the like in the Artemisia princeps plant body. They are extracted through the known methods and the extract can be used directly as it is, in the form of the concentrate thereof, or after evaporation to the dryness, in any forms. The formulation of these extracts is some 0.001-10 wt.%, preferably in an amount of 0.01-5 wt.%, more preferably 0.05-1 wt.%.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の分野】本発明は皮膚外用組成物、さらに詳しく
は、かゆみの防止及び抑制並びに創傷治癒や、肌あれ防
止、肌あれの改善等に優れた化粧料、医薬、医薬部外品
として有用な保湿性の皮膚外用貼付剤に関する。
FIELD OF THE INVENTION The present invention is useful as a composition for external use on the skin, and more particularly, as a cosmetic, pharmaceutical or quasi-drug excellent in prevention and suppression of itching, wound healing, prevention of skin roughening and improvement of skin roughening. A highly moisturizing skin patch for external use.

【0002】[0002]

【従来の技術】かゆみは皮膚上層に刺激が加わることに
より起こり、その刺激となる化学物質としてはヒスタミ
ンがよく知られている。ヒスタミンは肥満細胞からの脱
顆粒により組織内に遊離し、かゆみを起こす(久保田淳
ほか編集:現代皮膚科学体系3C、石橋康正ほか編集:
痒みの強い皮膚疾患)。かゆみを伴う疾患にはアトピー
性のものや老人性掻痒症などの乾燥性掻痒症が挙げられ
るが、このような皮膚疾患は患者に精神的苦痛を与え、
また掻くことにより症状を悪化させる。従来、このよう
な皮膚疾患を予防または治療すべく、各種の外用剤が提
案されている。このうち、皮膚に対する緩和な作用から
生薬を主成分とするものが注目されている(例えば、特
開平1−319424号公報)が効果は充分でない。ま
た、鎮痒成分、殺菌成分あるいは保湿成分を基剤中に配
合することにより老人性乾皮症、皮膚角化症、アトピー
性の症状などに有効な貼付剤が知られている(特開平9
−110680号公報)。しかしながら、これらの外用
剤も効果の持続性などの点で充分ではない。
2. Description of the Related Art Itching is caused by irritation to the upper layer of the skin, and histamine is well known as a stimulating chemical substance. Histamine is released into the tissue by degranulation from mast cells and causes itching (Edited by Jun Kubota et al .: Modern dermatology 3C, edited by Yasumasa Ishibashi et al .:
Itchy skin disease). Itchy diseases include atopic pruritus and dry pruritus such as senile pruritus, but such skin disorders can cause mental distress to patients,
Scratching also exacerbates the symptoms. Conventionally, various external preparations have been proposed to prevent or treat such skin diseases. Of these, those containing a crude drug as a main component have attracted attention because of their mild action on the skin (for example, JP-A-1-319424), but the effect is not sufficient. Also, a patch is known which is effective for senile xerosis, cutaneous keratosis, atopic symptoms and the like by incorporating an antipruritic component, a bactericidal component or a moisturizing component into a base (Japanese Patent Application Laid-Open No. Hei 9 (1999)).
-110680 gazette). However, these external preparations are not sufficient in terms of the persistence of the effect.

【0003】[0003]

【発明の目的及び概要】本発明の目的は持続性に優れた
鎮痒効果を示す皮膚外用貼付剤を提供するものである。
OBJECTS AND SUMMARY OF THE INVENTION An object of the present invention is to provide an external skin patch having an antipruritic effect with excellent durability.

【0004】本発明者らは前記の事情に鑑みて実際の臨
床の場において優れた持続性を有する鎮痒性外用剤につ
いて検討を行うにあたりヨモギ抽出物に注目し、これに
所定の薬剤を併用して貼付剤に配合することによって持
続性のある保湿作用、鎮痒作用が得られるとの知見を得
て本発明を完成するに至った。
[0004] In view of the above circumstances, the present inventors have paid attention to mugwort extract when examining an antipruritic topical agent having excellent durability in actual clinical settings. The present inventors have found that a long-lasting moisturizing effect and an antipruritic effect can be obtained by adding the compound to a patch, thereby completing the present invention.

【0005】本発明は、ヨモギ抽出物と、抗ヒスタミン
剤及び鎮痒剤から選ばれた少なくとも1種の薬剤成分と
を配合してなる皮膚外用貼付剤を提供するものである。
本発明は、これに加えて地楡、杜松葉、杉葉、蓮根、三
七人参、地骨皮、茜根及びクララから選ばれた少なくと
も1種の植物エキスを配合するのが好ましく、また、さ
らに殺菌剤を配合してもよい。本発明の貼付剤は保湿性
及び鎮痒性を持続する。
[0005] The present invention provides an external skin patch comprising a mugwort extract and at least one drug component selected from antihistamines and antipruritics.
In the present invention, in addition to this, it is preferable to blend at least one plant extract selected from Jiyu, pine needles, cedar leaves, lotus root, radish, dermis, Akane root and Clara, Further, a bactericide may be blended. The patch of the present invention maintains moisture retention and antipruritic properties.

【0006】[0006]

【発明の実施の形態】(ヨモギ抽出物)本発明で用いら
れるヨモギ抽出物は特に限定されるものではない。抽出
原料としては、ヨモギの葉、茎などをいずれも用いるこ
とができ、これらを公知の方法で抽出した抽出液そのも
の、その濃縮物、あるいは乾固したものがいずれも用い
られる。
BEST MODE FOR CARRYING OUT THE INVENTION (Mugwort extract) The mugwort extract used in the present invention is not particularly limited. As an extraction raw material, any of mugwort leaves, stems and the like can be used, and any of the extract itself extracted by a known method, a concentrate thereof, and a dried product are used.

【0007】抽出は、水または中間極性を有する溶媒、
一価もしくは多価の低級アルコールまたはこれらの混合
溶媒で行うことができる。中間極性を有する溶媒として
は、例えば、エチルエーテル、クロロホルム、酢酸エチ
ル、アセトン等が挙げられる。一価の低級アルコールと
しては、メタノール、エタノール、プロパノール、ブタ
ノールのような炭素数1〜4のアルコールが、また、多
価の低級アルコールとしては、プロピレングリコール、
1,3−ブチレングリコールなどのグリコール類やグリ
セリンのような二価または三価の低級アルコールが挙げ
られる。これらは単独で用いてもよく、また2種以上を
混合して用いてもよい。こらのうち、抽出効率から、特
に、水またはエタノールが好適である。
The extraction comprises water or a solvent of intermediate polarity,
The reaction can be carried out with a monohydric or polyhydric lower alcohol or a mixed solvent thereof. Examples of the solvent having an intermediate polarity include ethyl ether, chloroform, ethyl acetate, acetone and the like. Examples of the monohydric lower alcohol include alcohols having 1 to 4 carbon atoms such as methanol, ethanol, propanol, and butanol, and examples of the polyvalent lower alcohol include propylene glycol,
Examples thereof include glycols such as 1,3-butylene glycol and dihydric or trihydric lower alcohols such as glycerin. These may be used alone or as a mixture of two or more. Among them, water or ethanol is particularly preferable from the viewpoint of extraction efficiency.

【0008】抽出条件は特に制限されるものではなく、
例えば原料ヨモギに対して約1〜30体積倍量の抽出溶
媒に常温または加熱下(50〜80℃)で適宜の時間
(1〜8時間)、1〜数回、浸漬する方法が挙げられ
る。さらに、ろ過または遠心分離による固形物の除去、
活性炭による脱色、合成高分子吸着体などによる樹脂処
理を行なうなど、公知の方法により精製することができ
る。しかし、該抽出エキスの抗かゆみ、鎮痒効果は未精
製の抽出物のままでも強く発現するので、色、におい、
安定性等の点で不都合がない限り、高度の精製は通常不
要である。
[0008] The extraction conditions are not particularly limited.
For example, a method of immersing in an extraction solvent of about 1 to 30 times the volume of the raw mugwort at room temperature or under heating (50 to 80 ° C.) for an appropriate time (1 to 8 hours) for one to several times can be mentioned. In addition, removal of solids by filtration or centrifugation,
Purification can be performed by a known method, such as decolorization with activated carbon or resin treatment with a synthetic polymer adsorbent. However, the anti-itch, antipruritic effect of the extract is strongly expressed even with the unpurified extract, so the color, smell,
As long as there is no inconvenience in terms of stability or the like, a high degree of purification is usually unnecessary.

【0009】このような抽出エキスの配合量は、剤形、
目的とする抗かゆみ効果の程度などによって異なるが、
通常、組成物全量に対して、エキスの固形分換算で0.
001〜10重量%、好ましくは0.01〜5重量%、
さらに好ましくは0.05〜1重量%程度である。
[0009] The amount of the extracted extract is determined by the dosage form,
Depends on the desired anti-itch effect, etc.
Usually, the total amount of the composition is 0.
001 to 10% by weight, preferably 0.01 to 5% by weight,
More preferably, it is about 0.05 to 1% by weight.

【0010】配合量がこれより少ないと保湿感性が持続
せず抗かゆみ効果が充分でない。一方、この範囲を越え
ると効果は配合量に比例して増加せず、また長期使用す
ると皮膚感作作用が起こり好ましくない。さらに植物抽
出液特有の臭いや着色が生じ、商品価値を損なう恐れが
ある。
If the amount is less than this, the moisturizing feeling is not maintained and the anti-itch effect is not sufficient. On the other hand, when the amount exceeds this range, the effect does not increase in proportion to the amount, and when used for a long time, a skin sensitizing effect occurs, which is not preferable. Furthermore, the smell and coloring peculiar to the plant extract are generated, which may impair the commercial value.

【0011】(薬剤成分)本発明の貼付剤に配合される
抗ヒスタミン剤、鎮痒剤、殺菌剤は特に限定されるもの
ではないが、つぎのものが好ましく配合される。抗ヒス
タミン剤としては、塩酸ジフェンヒドラミン、サリチル
酸ジフェンヒドラミン、ジフェンヒドラミン、マレイン
酸クロルフェニラミン、ジフェニルイミダゾールなどが
挙げられ、好ましくは塩酸ジフェンヒドラミン、サリチ
ル酸ジフェンヒドラミンである。鎮痒剤としては、クロ
タミトンが挙げられる。
(Drug component) The antihistamine, antipruritic and bactericide to be incorporated in the patch of the present invention are not particularly limited, but the following are preferably incorporated. Examples of the antihistamine include diphenhydramine hydrochloride, diphenhydramine salicylate, diphenhydramine, chlorpheniramine maleate, diphenylimidazole, and the like, and preferably diphenhydramine hydrochloride and diphenhydramine salicylate. Antipruritic agents include crotamiton.

【0012】また、殺菌剤としては、チモール、イソプ
ロパノール、塩化ベンザルコニウム、塩化ベンゼトニウ
ム、グルコン酸クロルヘキシジン、塩酸クロルヘキシジ
ン、イソプロピルメチルフェノール、サリチル酸、ポピ
ドンヨードなどが挙げられ、特にチモールが好ましい。
これら殺菌剤の配合量は組成物全量に対して0.01〜
5重量%、好ましくは0.1〜3重量%である。これら
の薬効成分は、単独で用いてもよく、また2種以上を併
用してもよい。これらのうち、特に塩酸ジフェンヒドラ
ミン、クロタミトンを用いると、ヨモギ抽出物との優れ
た相乗効果が発揮され好ましい。これら薬効成分の配合
量は組成物全量に対して0.01〜5重量%、好ましく
は0.1〜3重量%である。
[0012] Examples of the fungicide include thymol, isopropanol, benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, chlorhexidine hydrochloride, isopropylmethylphenol, salicylic acid, and povidone-iodine, and thymol is particularly preferred.
The content of these fungicides is 0.01 to the total amount of the composition.
It is 5% by weight, preferably 0.1 to 3% by weight. These active ingredients may be used alone or in combination of two or more. Of these, diphenhydramine hydrochloride and crotamiton are particularly preferred because of their excellent synergistic effect with mugwort extract. The compounding amount of these medicinal ingredients is 0.01 to 5% by weight, preferably 0.1 to 3% by weight based on the total amount of the composition.

【0013】(植物エキス)本発明の外用組成物には、
さらに地楡、杜松葉、杉葉、蓮根、三七人参、地骨皮、
茜根及びクララから選ばれた少なくとも1種の植物エキ
スを配合するのが好ましい。これら植物エキスは公知の
方法で製造されるものであり、例えばつぎのようにして
抽出を行う。乾燥した生薬細切粉末(混合抽出物の場合
は各生薬細切粉末を等量づつ混合する)100gを50
%水性エタノール300ml中で3時間加熱還流し、ガ
ラスフィルターで濾過する。この処理をもう一度くり返
し、得られた濾液を合し、濃縮乾固して目的物を得る。
これら植物エキスの配合量は固形分換算で0.0001
〜3重量%である。この配合量が0.0001重量%に
満たないと保湿感が持続せず、一方、3重量%を越える
と臭いや着色などを生じるなど商品価値を損なう恐れが
ある。
(Plant Extract) The composition for external use of the present invention includes:
In addition, Jiyu, Morimatsuba, Sugiha, Lotus root, Three Ginseng, Jigoku skin,
It is preferable to mix at least one plant extract selected from Akane root and Clara. These plant extracts are produced by a known method. For example, extraction is performed as follows. 100 g of dried crude drug minced powder (in the case of a mixed extract, mix equal amounts of each crude drug minced powder)
Heat to reflux in 300 ml of 3% aqueous ethanol for 3 hours and filter through a glass filter. This process is repeated once more, the obtained filtrates are combined, and concentrated to dryness to obtain the desired product.
The amount of these plant extracts is 0.0001 in terms of solid content.
33% by weight. If the amount is less than 0.0001% by weight, the moisturizing feeling will not be maintained.

【0014】(貼付剤の製造)本発明の貼付剤は、一般
にパップ剤といわれ、ゼラチン等の水溶性ポリマーゲル
形成剤、カオリン等の充填剤および水を含むゲル状膏体
を不織布等の支持体上に塗布し、プラスチックフィルム
などのライナーで被覆した形態のものが代表的である。
この含水ゲル状膏体には、水に加えて湿潤剤としてグリ
セリン、プロピレングリコール、1,3−ブチレングリ
コール、ソルビトール、ポリエチレングリコール、プロ
ピレングリコールマンニトールなどの多価アルコールが
挙げられる。
(Preparation of Patch) The patch of the present invention is generally referred to as a poultice, and is used to support a gel-like plaster containing a water-soluble polymer gel-forming agent such as gelatin, a filler such as kaolin and water and a non-woven fabric or the like. A typical example is a form applied to the body and covered with a liner such as a plastic film.
In the water-containing gel-like plaster, in addition to water, a polyhydric alcohol such as glycerin, propylene glycol, 1,3-butylene glycol, sorbitol, polyethylene glycol, propylene glycol mannitol can be used as a wetting agent.

【0015】ゲル形成剤として、ポリアクリル酸/およ
びその塩、ゼラチン、カゼイン、カラギーナン、メチル
セルロース、カルボキシメチルセルロース、ポリビニル
アルコール、ヒドロキシプロピルセルロース、アルギン
酸ナトリウム、キサンタンガム、ポリビニルアルコー
ル、プルランなどが挙げられる。充填剤としては、カオ
リン、ベントナイト、酸化亜鉛、酸化チタン、タルク、
無水珪酸などが挙げられる。
Examples of the gel-forming agent include polyacrylic acid / a salt thereof, gelatin, casein, carrageenan, methylcellulose, carboxymethylcellulose, polyvinyl alcohol, hydroxypropylcellulose, sodium alginate, xanthan gum, polyvinyl alcohol and pullulan. As a filler, kaolin, bentonite, zinc oxide, titanium oxide, talc,
Silicic anhydride and the like can be mentioned.

【0016】また、ゲル状膏体には更に必要に応じて架
橋剤、界面活性剤、pH調整剤などを配合してもよい。
架橋剤としては、グリシナール、含水ケイ酸アルミニウ
ム、水酸化アルミニウム、水酸化アルミナ・マグメシウ
ムなどが挙げられる。界面活性剤としては、ポリオキシ
エチレン硬化ヒマシ油、プロピレングリコール脂肪酸エ
ステル、ポリオキシエチレンスルビタン脂肪酸エステ
ル、グリセリン脂肪酸エステル、ソルビタン脂肪酸エス
テル、ポリエチレングリコール脂肪酸エステル、ポリオ
キシエチレンモノステアレートなどが挙げられる。
The gel-like plaster may further contain a crosslinking agent, a surfactant, a pH adjuster, and the like, if necessary.
Examples of the crosslinking agent include glycinal, hydrous aluminum silicate, aluminum hydroxide, and alumina / magnesium hydroxide. Examples of the surfactant include polyoxyethylene hydrogenated castor oil, propylene glycol fatty acid ester, polyoxyethylene sulbitan fatty acid ester, glycerin fatty acid ester, sorbitan fatty acid ester, polyethylene glycol fatty acid ester, and polyoxyethylene monostearate.

【0017】pH調整剤としては、乳酸、酒石酸、クエ
ン酸、グルコン酸、リンゴ酸、マレイン酸などを用いる
ことができる。これら成分の配合量は、各々粘着剤1〜
20重量%、水10〜70重量%、湿潤剤10〜50重
量%、架橋剤0.005〜5重量%、界面活性剤0.1〜
5重量%、pH調整剤1〜10重量%の範囲が好まし
い。さらに、上記成分以外に通常外用剤に用いられる添
加物を適宜配合することができる。例えば、ヒアルロン
酸ナトリウム、コンドロイチン酸ナトリウム、尿素、マ
ルチトール、乳酸ナトリウム、プラセンタ等の保湿剤、
ハッカ油、ラベンダー、カモマイル、ユーカリ、ローズ
マリー、オレンジ、ローズ、キューカンバー、セージ、
ライム、レモン、ベルガモット、サフランなどの抽出物
など、オイル/エキスおよびメントール等の香料成分、
トコフェロール等のビタミン類、パラオキシ安息香酸エ
ステル類の防腐剤などが挙げられる。
As the pH adjuster, lactic acid, tartaric acid, citric acid, gluconic acid, malic acid, maleic acid, etc. can be used. The amounts of these components are as follows:
20% by weight, 10 to 70% by weight of water, 10 to 50% by weight of wetting agent, 0.005 to 5% by weight of crosslinking agent, 0.1 to 10% of surfactant
A range of 5% by weight and a pH adjuster of 1 to 10% by weight is preferable. Further, in addition to the above components, additives usually used in external preparations can be appropriately compounded. For example, humectants such as sodium hyaluronate, sodium chondroitin, urea, maltitol, sodium lactate, placenta,
Peppermint oil, lavender, camomile, eucalyptus, rosemary, orange, rose, cucumber, sage,
Fragrance ingredients such as oils / extracts and menthol, such as extracts of lime, lemon, bergamot, saffron, etc.
Preservatives such as vitamins such as tocopherol and paraoxybenzoic acid esters are included.

【0018】また、支持体は、特に限定されるものでは
ないが、ポリエステル、ポリプロピレン、レーヨン等の
不織布、織布、編布及び皮膚に貼付し違和感のないポリ
エチレン、ポリプロピレン、ポリウレタン等エラストマ
ーのフィルム、シートなどから選択される。本発明の皮
膚貼付剤は、老人性掻痒症、乾燥性掻痒症、アトピー性
などのかゆみを伴う皮膚疾患部に、1日に1〜2回貼
付、特に夜間就寝前の貼付により、皮膚の乾燥を防ぎ、
皮膚のカサツキ、炎症等の症状の改善、かゆみの抑制が
はかられ、且つそれらの効果が持続する。さらに、皮膚
疾患部が貼付剤により被覆保護され、外部刺激から回避
できる。
The support is not particularly limited, but may be a nonwoven fabric such as polyester, polypropylene, or rayon, a woven fabric, a knitted fabric, or a film of an elastomer such as polyethylene, polypropylene, or polyurethane that can be applied to the skin without causing discomfort. It is selected from a sheet or the like. The skin patch of the present invention is applied once or twice a day to a dermatologically irritated part such as senile pruritus, dry pruritus, or atopic sensation. Prevent
Improvement of symptoms such as skin swelling and inflammation and suppression of itch are maintained, and their effects are maintained. Furthermore, the skin diseased part is covered and protected by the patch, and can be avoided from external stimuli.

【0019】[0019]

【実施例】つぎに実施例及び比較例により本発明をさら
に詳しく説明する。本発明がこれら実施例に限られない
ことは言うまでもない。また、特に断わらないかぎり実
施例中の[%]は[重量%]を意味する。
Next, the present invention will be described in more detail with reference to Examples and Comparative Examples. It goes without saying that the present invention is not limited to these embodiments. Unless otherwise specified, [%] in Examples means [% by weight].

【0020】[実施例1〜3]下記の表1に示す各成分
を、加湿式混合機を用いて常法に従い均一に練合した。
得られたゲル状膏体を、直ちに不織布上に塗布量が10
00g/m2になるように延転し、ポリエステルフィルム
で被覆して、皮膚貼付剤を調製した。 [比較例1〜2]前記実施例の成分から各エキス成分を
除いたもの及び抗ヒスタミン剤、鎮痒剤を除いた処方の
膏体を調製し、実施例と同様にして貼付剤を得た。
Examples 1 to 3 The components shown in Table 1 below were uniformly kneaded using a humidifying mixer according to a conventional method.
Immediately apply the obtained gel-like plaster on the nonwoven fabric in an amount of 10
It was rolled to 00 g / m 2 and covered with a polyester film to prepare a skin patch. [Comparative Examples 1 and 2] A plaster was prepared in the same manner as in the Example, except that the extract was prepared by removing the extract components and the antihistamine and the antipruritic except for the antipruritic agent.

【0021】[0021]

【表1】皮膚貼付剤の処方 [Table 1] Formulation of skin patch

【0022】[結果]実施例及び比較例にて得られた貼
付剤のサンプル(10cm×14cm)を自覚症状のある
患者に下記のとおり使用してその経過を確認した。年齢
が10〜60歳代のアトピー性皮膚炎の患者20人に就
寝時に5〜8時間患部皮膚に貼付し、その症状の変化を
10段階で評価し判定した(貼付前を10とし完全に良
化したものを1とする)。その結果を表2に示す。ヨモ
ギエキス成分を加えることにより、薬剤成分のみの場合
より優位に改善された。
[Results] The patch samples (10 cm × 14 cm) obtained in Examples and Comparative Examples were used in patients with subjective symptoms as follows, and the progress was confirmed. 20 patients with atopic dermatitis in their 10s and 60s were affixed to the affected skin at bedtime for 5-8 hours at bedtime, and the changes in their symptoms were evaluated and evaluated on a 10-point scale. Is 1). Table 2 shows the results. By adding the mugwort extract component, the improvement was superior to the case of the drug component alone.

【0023】[0023]

【表2】 自覚症状の改善度 ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 症状の改善度(平均値) 症 状 使用前 2週間後 4週間後 ───────────────────────────────── 実施例1 かゆみ 10 2.2 2.2 乾燥(カサツキ感) 10 6.0 3.2 〃 2 かゆみ 10 2.2 1.8 乾燥(カサツキ感) 10 3.6 2.2 〃 3 かゆみ 10 1.8 1.4 乾燥(カサツキ感) 10 3.0 1.6 〃 4 かゆみ 10 1.8 1.4 乾燥(カサツキ感) 10 4.0 2.6 ───────────────────────────────── 比較例1 かゆみ 10 2.0 2.0 乾燥(カサツキ感) 10 4.8 3.0 〃 2 かゆみ 10 7.6 6.4 乾燥(カサツキ感) 10 6.4 3.8 ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━[Table 2] Improvement of subjective symptoms 度 Improvement of symptoms (average value) Symptom Before use After 2 weeks After 4 weeks ───────────────────────────────── Example 1 Itching 10 2. 2 2.2 Drying (Roughness) 10 6.0 3.2〃2 Itching 10 2.2 1.8 Drying (Roughness) 10 3.6 2.2〃3 Itching 10 1.8 1.4 Drying ( 10 3.0 1.6 〃 4 Itching 10 1.8 1.4 Dry (scratch) 10 4.0 2.6 ──────────────────比較 Comparative Example 1 Itching 10 2.0 2.0 Drying (Roughness) 10 4.8 3.0 〃 2 Itching 10 7.6 6.4 Drying ( Roughness) 10 6.4 3.8 ━━━━━━━━ ━━━━━━━━━━━━━━━━━━━━━━━━

【0024】[0024]

【発明の効果】本発明の皮膚概要貼付剤は保湿作用があ
り、持続性に優れた鎮痒効果を示す。
EFFECT OF THE INVENTION The skin outline patch of the present invention has a moisturizing effect and exhibits a long-lasting antipruritic effect.

───────────────────────────────────────────────────── フロントページの続き Fターム(参考) 4C076 AA72 AA81 BB31 CC18 DD27 DD28 DD29 DD37A DD38 DD43 DD45R DD46 DD49A DD52A EE09A EE23A EE32A EE42 EE53 EE58A FF31 4C083 AA111 AA112 AB242 AB372 AB442 AC122 AC132 AC302 AC432 AC442 AC472 AC482 AC552 AC642 AD042 AD092 AD272 AD432 CC03 DD22 DD27 EE12 EE13 4C088 AB03 AB14 AB18 AB29 AB39 AB48 AB51 AB59 AC04 AC05 AC11 AC13 BA08 BA09 BA10 MA02 MA08 MA32 MA63 NA12 ZA89  ──────────────────────────────────────────────────続 き Continued on the front page F term (reference) 4C076 AA72 AA81 BB31 CC18 DD27 DD28 DD29 DD37A DD38 DD43 DD45R DD46 DD49A DD52A EE09A EE23A EE32A EE42 EE53 EE58A FF31 4C083 AA111 AA112 AB242 AB372 AC442 AC432AC302 AC302 AD092 AD272 AD432 CC03 DD22 DD27 EE12 EE13 4C088 AB03 AB14 AB18 AB29 AB39 AB48 AB51 AB59 AC04 AC05 AC11 AC13 BA08 BA09 BA10 MA02 MA08 MA32 MA63 NA12 ZA89

Claims (4)

【特許請求の範囲】[Claims] 【請求項1】ヨモギ抽出物と、抗ヒスタミン剤及び鎮痒
剤から選ばれた少なくとも1種の薬剤成分とを配合して
なる皮膚外用貼付剤。
An external skin patch comprising a mugwort extract and at least one drug component selected from an antihistamine and an antipruritic.
【請求項2】さらに、地楡、杜松葉、杉葉、蓮根、三七
人参、地骨皮、茜根及びクララから選ばれた少なくとも
1種の植物エキスを配合してなる請求項1の皮膚外用貼
付剤。
2. The skin according to claim 1, further comprising at least one plant extract selected from the group consisting of Jiuyu, Juniper, Sugiha, Lotus root, Three ginseng, dermis, Akane root and Clara. External patch.
【請求項3】さらに、殺菌剤を配合してなる請求項1又
は2の皮膚外用貼付剤。
3. The external patch for skin according to claim 1, further comprising a bactericide.
【請求項4】 貼付剤が保湿性及び鎮痒性を有するもの
である請求項1〜3のいずれかの皮膚外用貼付剤。
4. The external patch for skin according to claim 1, wherein the patch has a moisturizing property and an antipruritic property.
JP11105073A 1999-04-13 1999-04-13 Transdermal patch for external use for skin Pending JP2000297044A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP11105073A JP2000297044A (en) 1999-04-13 1999-04-13 Transdermal patch for external use for skin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11105073A JP2000297044A (en) 1999-04-13 1999-04-13 Transdermal patch for external use for skin

Publications (1)

Publication Number Publication Date
JP2000297044A true JP2000297044A (en) 2000-10-24

Family

ID=14397778

Family Applications (1)

Application Number Title Priority Date Filing Date
JP11105073A Pending JP2000297044A (en) 1999-04-13 1999-04-13 Transdermal patch for external use for skin

Country Status (1)

Country Link
JP (1) JP2000297044A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003055241A (en) * 2001-08-09 2003-02-26 Lion Corp Skin care preparation for preventing itchiness
KR20040017013A (en) * 2002-08-20 2004-02-26 국양임 Band using artemisia
WO2005053722A1 (en) * 2003-12-05 2005-06-16 Toyo R & D Inc. Antiallergic agent containing ground lotus and/or extract thereof together with lactic acid bacterium
KR100524149B1 (en) * 2002-08-20 2005-10-26 김진섭 A process for producing a composition presenting an effect of moxacautery and pharmaceutically acceptable preparations using the same
JP2006181364A (en) * 2004-12-27 2006-07-13 Bristol Myers Squibb Co Enzyme inhibition adhesive
FR2924610A1 (en) * 2007-12-10 2009-06-12 Lvmh Rech COSMETIC COMPOSITION CONTAINING LOTUS EXTRACT AND COSMETIC CARE METHOD USING THE SAME.
JPWO2009084611A1 (en) * 2007-12-28 2011-05-19 株式会社瑞光 Anti-itch sheet
CN102579664A (en) * 2012-03-05 2012-07-18 王敬祥 Traditional Chinese medicine for quick healing of postoperative incision
CN103463199A (en) * 2012-06-07 2013-12-25 林胜杰 Composition for subcutaneous tissue trauma
CN103599234A (en) * 2013-11-25 2014-02-26 黎芷杉 Traditional Chinese medicinal liquid for preventing and treating wound infection and preparation method thereof

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55127317A (en) * 1979-03-23 1980-10-02 Sunstar Inc External skin drug composition comprising crude drug
JPH01102027A (en) * 1987-10-15 1989-04-19 Nitto Denko Corp Production of antiallergic drug
JPH01128933A (en) * 1987-11-12 1989-05-22 Shiseido Co Ltd Hyaluronidase inhibitor
JPH0517330A (en) * 1991-07-03 1993-01-26 Fujii Kk Therapeutic agent for common acne
JPH06211679A (en) * 1993-01-18 1994-08-02 Sunstar Inc Antiinflammatory and antipruritic external preparation
JPH06279305A (en) * 1993-03-25 1994-10-04 Kuga Takaaki Agent for treatment of dermatic disease such as atopic dermatitis
JPH0873364A (en) * 1994-08-31 1996-03-19 Ichimaru Pharcos Co Ltd Antibacterial and antiseptic agent containing extract of sophora flvescens aitin and cosmetic
JPH09110680A (en) * 1995-10-19 1997-04-28 Yuutoku Yakuhin Kogyo Kk Dermatitis-curing strap
JPH1017461A (en) * 1996-06-28 1998-01-20 Shiseido Co Ltd Preparation for external use for improving skin roughness
JPH10139679A (en) * 1996-11-05 1998-05-26 Noevir Co Ltd Isolation inhibitor of chemical mediator, and cosmetic, medicine and food including the same
JPH10287580A (en) * 1997-04-10 1998-10-27 Motoo Nishimura Preparation for external use
JP2000044481A (en) * 1998-07-30 2000-02-15 Sunstar Inc Preparation for external use for skin

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55127317A (en) * 1979-03-23 1980-10-02 Sunstar Inc External skin drug composition comprising crude drug
JPH01102027A (en) * 1987-10-15 1989-04-19 Nitto Denko Corp Production of antiallergic drug
JPH01128933A (en) * 1987-11-12 1989-05-22 Shiseido Co Ltd Hyaluronidase inhibitor
JPH0517330A (en) * 1991-07-03 1993-01-26 Fujii Kk Therapeutic agent for common acne
JPH06211679A (en) * 1993-01-18 1994-08-02 Sunstar Inc Antiinflammatory and antipruritic external preparation
JPH06279305A (en) * 1993-03-25 1994-10-04 Kuga Takaaki Agent for treatment of dermatic disease such as atopic dermatitis
JPH0873364A (en) * 1994-08-31 1996-03-19 Ichimaru Pharcos Co Ltd Antibacterial and antiseptic agent containing extract of sophora flvescens aitin and cosmetic
JPH09110680A (en) * 1995-10-19 1997-04-28 Yuutoku Yakuhin Kogyo Kk Dermatitis-curing strap
JPH1017461A (en) * 1996-06-28 1998-01-20 Shiseido Co Ltd Preparation for external use for improving skin roughness
JPH10139679A (en) * 1996-11-05 1998-05-26 Noevir Co Ltd Isolation inhibitor of chemical mediator, and cosmetic, medicine and food including the same
JPH10287580A (en) * 1997-04-10 1998-10-27 Motoo Nishimura Preparation for external use
JP2000044481A (en) * 1998-07-30 2000-02-15 Sunstar Inc Preparation for external use for skin

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003055241A (en) * 2001-08-09 2003-02-26 Lion Corp Skin care preparation for preventing itchiness
KR20040017013A (en) * 2002-08-20 2004-02-26 국양임 Band using artemisia
KR100524149B1 (en) * 2002-08-20 2005-10-26 김진섭 A process for producing a composition presenting an effect of moxacautery and pharmaceutically acceptable preparations using the same
WO2005053722A1 (en) * 2003-12-05 2005-06-16 Toyo R & D Inc. Antiallergic agent containing ground lotus and/or extract thereof together with lactic acid bacterium
US7709032B2 (en) 2003-12-05 2010-05-04 Toyo R&D Inc. Anti-allergic agent containing both ground lotus and/or extract and lactic acid bacterium
JP2006181364A (en) * 2004-12-27 2006-07-13 Bristol Myers Squibb Co Enzyme inhibition adhesive
FR2924610A1 (en) * 2007-12-10 2009-06-12 Lvmh Rech COSMETIC COMPOSITION CONTAINING LOTUS EXTRACT AND COSMETIC CARE METHOD USING THE SAME.
US8753693B2 (en) 2007-12-10 2014-06-17 Lvmh Recherche Cosmetic composition containing an extract from lotus and method of cosmetic care using said composition
JPWO2009084611A1 (en) * 2007-12-28 2011-05-19 株式会社瑞光 Anti-itch sheet
CN102579664A (en) * 2012-03-05 2012-07-18 王敬祥 Traditional Chinese medicine for quick healing of postoperative incision
CN103463199A (en) * 2012-06-07 2013-12-25 林胜杰 Composition for subcutaneous tissue trauma
CN103599234A (en) * 2013-11-25 2014-02-26 黎芷杉 Traditional Chinese medicinal liquid for preventing and treating wound infection and preparation method thereof

Similar Documents

Publication Publication Date Title
KR102309958B1 (en) A cosmetic composition for skin improvement comprising bulb extract
EP0621787A1 (en) Skin therapeutic mixture containing cold-processed aloe vera extract, with yellow sap and aloin removed
WO2008140200A1 (en) External compositions for the skin
US8784875B2 (en) Collagen for use in the treatment of skin diseases
EP2214658A1 (en) Osmolyte-containing preparation for use in case of dry mucous membranes
JP4596751B2 (en) Anti-inflammatory analgesic patch
JP4677063B2 (en) Dutch mustard extract combination external preparation
JPH08188527A (en) Sheet-like pack agent
JP2000297044A (en) Transdermal patch for external use for skin
KR102189330B1 (en) A cosmetic composition for skin improvement comprising bulb extract
US20060099166A1 (en) Honey-based skin care preparation
JP4575632B2 (en) Drugs for migraine relief
CN105267866A (en) Emulsion for treating onychomycosis and preparation method of emulsion for treating onychomycosis
JPH08291057A (en) Cataplasm
RU2405534C1 (en) Anti-acne cream gel
JP5699184B2 (en) Carbon dioxide transdermal / mucosal absorption composition
RU2412719C2 (en) Anti-eczema medication "pro-xylane"
CN105169463B (en) A kind of cation baby's medical dressing and preparation method thereof
CN100408091C (en) Recombination human granul ocyte-macrophage colong stimulating factor ges and its preparation method
JP2003055138A (en) Sheet cosmetic containing propolis
US20240415767A1 (en) Tattoo Aftercare Sealant Gel
KR101465843B1 (en) Natural dye toilet papers for curing a hemorrhoids and the method of manufacturing thereof
RU2681851C1 (en) Anti-burn means
DE202012000247U1 (en) Composition for topical application II
WO2018188197A1 (en) Antibacterial and anti-inflammatory drug and preparation method therefor

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090915

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100406